Bright Minds Biosciences Inc Ordinary Shares DRUG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $69.00
- Day Range
- $61.84–70.71
- 52-Week Range
- $23.18–123.75
- Bid/Ask
- $53.00 / $75.50
- Shares Outstanding
- 9.81M
- Market Cap
- $640.53M
- Volume/Avg
- 352,619 / 226,029
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 25
- Website
- https://www.brightmindsbio.com
Valuation
|
Metric
|
DRUG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.06 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DRUG
|
|---|---|
Quick Ratio | 81.10 |
Current Ratio | 81.48 |
Interest Coverage | — |
Quick Ratio
DRUG
Profitability
|
Metric
|
DRUG
|
|---|---|
Return on Assets (Normalized) | −17.73% |
Return on Equity (Normalized) | −18.01% |
Return on Invested Capital (Normalized) | −21.83% |
Return on Assets
DRUG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Zmplnzpqm | Vkhmvf | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vmcjmlxl | Rkdwg | $67B | |||
| argenx SE ADR
ARGX
| Wyghhnwfw | Ncmk | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pbpqbmkhy | Whklkx | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Drwmhskqd | Gjctfmq | $25B | |||
| BioNTech SE ADR
BNTX
| Dsztvrgy | Kfdl | $22B | |||
| Incyte Corp
INCY
| Zgwrrnpq | Vvb | $20B | |||
| Moderna Inc
MRNA
| Xwsssjdw | Rpcpd | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Gqlyylkps | Rmfq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Qqsnhrnh | Bxdg | $13B |
United States